Evidence map›Paper›PMID 42251495›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Luciana Mascarenhas Fonseca, Eardi Lila, Ali Shojaie, Jasmeer Chhatwal, Orestes Forlenza, Michal Schnaider Beeri, Sharon Krinsky-McHale, Ann D Cohen, Bradley T Christian, Elizabeth Head and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Luciana Mascarenhas FonsecaThe Krieger Klein Alzheimer's Research Center, Rutgers Health, New Brunswick, New Jersey, USA.ORCID https://orcid.org/0000-0002-2849-0545
Eardi LilaDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Ali ShojaieDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Jasmeer ChhatwalDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Orestes ForlenzaLaboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of São Paulo School of Medicine, São Paulo, São Paulo, Brazil.
Michal Schnaider BeeriThe Krieger Klein Alzheimer's Research Center, Rutgers Health, New Brunswick, New Jersey, USA.
Sharon Krinsky-McHaleNew York State Institute for Basic Research in Developmental Disabilities, New York, New York, USA.
Ann D CohenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Bradley T ChristianWisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Elizabeth HeadDepartment of Pathology and Laboratory Medicine, University of California, Irvine, California, USA.
Mark MapstoneDepartment of Neurology, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California, USA.
Benjamin HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Beau M AncesDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Thomas GrabowskiDepartments of Radiology and Neurology, University of Washington, Seattle, Washington, USA.
Naomi S ChaytorDepartment of Community and Behavioral Health, Elson S Floyd College of Medicine, Washington State University, Spokane, Washington, USA.
Shahid ZamanDepartment of Psychiatry, University of Cambridge, Cambridge, Cambridgeshire, UK.
Alzheimer's Biomarkers Consortium‐ Down Syndrome (ABC‐DS) Investigators

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTIAN, BRADLEY T, HANDEN, BENJAMIN L · 2020 to 2025
$103.7M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI YASSA, MICHAEL A · 2000 to 2019
$37.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Centralized Repository for Alzheimer Disease and Related Dementias U24 AG21886National Institute on Aging (NIA)National Institutes of Health (NIA-NIH) K99/R00National Institutes of Health (NIA-NIH) R00AG082864NCATS NIH HHS UL1 TR001414NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002366NCATS NIH HHS UL1 TR002373NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG072973NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS U01 AG051406NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054NICHD NIH HHS P50 HD105353NIHR Cambridge Biomedical Research Centrethe NIAWindsor Research Unit, CPFT, Fulbourn Hospital Cambridge, UK.
6 · The paper itself

Abstract

introductionAdults with Down syndrome (DS) are at risk for Alzheimer's disease (AD), yet identifying the preclinical phase remains challenging. Intraindividual cognitive variability (IICV) may be a sensitive marker of early AD-related changes but remains understudied in DS.

methodsAdults from the Alzheimer's Biomarker Consortium-DS (ABC-DS) study (N = 460, mean age 43.3 years; 45.7% female) were included. Generalized linear models examined whether baseline IICV predicted incident mild cognitive impairment (MCI)/dementia, cognitive decline, and amyloid and tau positron emission tomography outcomes, adjusting for demographics, intellectual disability, apolipoprotein E ε4, site, assessment interval, and mean cognitive performance, with Bonferroni correction.

resultsGreater IICV predicted incident MCI/dementia (odds ratio = 4.63 to 5.13, p < 0.05), greater amyloid burden, early tau accumulation, and higher tau across Braak stages, independent of mean cognition. Exploratory analyses suggested sex-specific interactions with tau outcomes. DISCUSSION: IICV is a sensitive marker of dementia risk and cognitive resilience in DS, with potential utility for secondary prevention and trial enrichment.

Indexed as

Amyloid beta-PeptidesCognitionCognitive DysfunctionDementiaDown Syndrometau ProteinsAlzheimer DiseaseBiomarkersDisease ProgressionFemaleHumansMaleMiddle AgedNeuropsychological TestsPositron-Emission TomographyAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer's diseasecognitioncognitive variabilitydementiadispersionDown syndromeintellectual disabilityneuroimagingresilience

Identifiers

PMID42251495
PMCPMC13242613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.